Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3 Pt 1
|
pubmed:dateCreated |
1992-7-30
|
pubmed:abstractText |
To determine the role of maintenance steroids in a cyclosporine and azathioprine immunosuppressive regimen, 112 heart transplant recipients were prospectively randomized to group I (n = 59; cyclosporine, azathioprine, and prednisolone) or group II (n = 53; cyclosporine and azathioprine). All patients received 7 days of induction with antithymocyte globulin. Patients receiving double-drug therapy who required four treatments for rejection were converted to maintenance steroids. This was necessary in 47% of the patients. Actuarial survival at 5 years was 82% in group I and 85% in group II. Linearized rejection in the first 3 months was lower with triple-drug therapy than with double-drug therapy (1.5 +/- 0.18 versus 2.3 +/- 0.23 episodes/100 patient days, p less than 0.01) but did not differ beyond 3 months. No significant differences were noted in 3-year left ventricular ejection fraction (0.56 +/- 0.09 versus 0.58 +/- 0.12 units), serum creatinine level (0.14 +/- 0.04 versus 0.14 +/- 0.03 mmol/L), or number with coronary artery disease (10 versus 13), diabetes, or bone complications. Patients receiving triple-drug therapy, however, had higher serum cholesterol level at 3 years (6.2 +/- 0.9 versus 5.4 +/- 1.2 mmol/L; p = 0.022) and required more antihypertensive agents (1.3 +/- 0.8 versus 0.8 +/- 0.6; p = 0.016). Similar trends emerged when patients receiving true double-drug therapy were compared with those patients who were "converted." Therapy with double versus triple immunosuppressive therapy results in similar 5-year survival and systolic function, using this protocol of converting recurrent rejectors on double-drug therapy to maintenance steroids.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1053-2498
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
550-5; discussion 556
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1610863-Actuarial Analysis,
pubmed-meshheading:1610863-Adult,
pubmed-meshheading:1610863-Azathioprine,
pubmed-meshheading:1610863-Cyclosporine,
pubmed-meshheading:1610863-Female,
pubmed-meshheading:1610863-Follow-Up Studies,
pubmed-meshheading:1610863-Graft Rejection,
pubmed-meshheading:1610863-Heart Transplantation,
pubmed-meshheading:1610863-Humans,
pubmed-meshheading:1610863-Immunosuppression,
pubmed-meshheading:1610863-Immunosuppressive Agents,
pubmed-meshheading:1610863-Male,
pubmed-meshheading:1610863-Prednisolone,
pubmed-meshheading:1610863-Prospective Studies,
pubmed-meshheading:1610863-Time Factors
|
pubmed:articleTitle |
Five-year follow-up of a randomized double-drug versus triple-drug therapy immunosuppressive trial after heart transplantation.
|
pubmed:affiliation |
Cardiopulmonary Transplant Unit, St. Vincent's Hospital, Sydney, New South Wales, Australia.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|